Engage Biologics announced that it has been acquired by Eli Lilly (LLY). Engage is developing the Tethosome platform, a non-viral DNA delivery system “designed to overcome key limitations in DNA delivery, including potency, tolerability, and redosability.” Lilly acquired Engage for up to $202M in cash, including an upfront payment and subsequent payments upon achievement of specified development milestones.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
- Eli Lilly Earnings Call Signals High-Growth Trajectory
- Morning News Wrap-Up, 5/19/26: Today’s Biggest Stock Market Stories!
- Eli Lilly Completes Key Olomorasib Drug Interaction Study, Clarifying Next Steps for KRAS Pipeline
- President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill